Compare · ABT vs MNPR
ABT vs MNPR
Side-by-side comparison of Abbott Laboratories (ABT) and Monopar Therapeutics Inc. (MNPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MNPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 375.9x MNPR ($481.9M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 6 for MNPR).
- ABT has more recent analyst coverage (25 ratings vs 15 for MNPR).
- Company
- Abbott Laboratories
- Monopar Therapeutics Inc.
- Price
- $104.88+0.16%
- $69.43-3.66%
- Market cap
- $181.14B
- $481.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 13
- 6
- Recent ratings
- 25
- 15
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest MNPR
- SEC Form 4 filed by Monopar Therapeutics Inc.
- Chief Operating Officer Cittadine Andrew converted options into 4,384 shares and covered exercise/tax liability with 1,944 shares, increasing direct ownership by 4% to 58,054 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Robinson Chandler converted options into 9,801 shares and covered exercise/tax liability with 4,344 shares, increasing direct ownership by 5% to 104,724 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Vu Quan Anh converted options into 614 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 20% to 2,655 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Monopar Therapeutics Inc.
- Chief Executive Officer Robinson Chandler exercised 29,056 shares at a strike of $21.74 and sold $2,556,851 worth of shares (29,056 units at $88.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan and exercised 4,090 shares at a strike of $22.04 (SEC Form 4)
- Amendment: Director Anderson Raymond exercised 3,142 shares at a strike of $30.00 and sold $351,835 worth of shares (3,142 units at $111.98) as part of a pre-agreed trading plan (SEC Form 4)
- Acting Chief Medical Officer Rioux Patrice exercised 1,380 shares at a strike of $0.01 and sold $111 worth of shares (1 units at $111.26) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 5,065 units (SEC Form 4)
- Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 7,396 units (SEC Form 4)